Literature DB >> 383169

Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.

Y Agid, G Barroche, A M Bonnet, F Javoy-Agid, G Kato, F Lhermitte, P Pollak, J L Signoret.   

Abstract

In this article, the clinical actions of the principal dopamine receptor stimulating agents (apomorphine and its derivatives; piribedil, rye-ergot derivatives) are discussed on the basis of their biochemical and pharmacological properties.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 383169

Source DB:  PubMed          Journal:  Biomedicine        ISSN: 0300-0893


  3 in total

Review 1.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

2.  Bromocriptine in Parkinson's disease: a study of cardiovascular effects.

Authors:  N Quinn; A Illas; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-05       Impact factor: 10.154

3.  Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.

Authors:  K Jellinger
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.